(Q44490961)

3 December 2017

title

A phase II/III study comparing intravenous ZD9331 with gemcitabine in patients with pancreatic cancer (English)

1 reference

3 December 2017

D Smith

1

1 reference

3 December 2017

N Gallagher

series ordinal

2

1 reference

3 December 2017

publication date

1 July 2003

1 reference

European Journal of Cancer

3 December 2017

published in

1 reference

3 December 2017

volume

39

1 reference

3 December 2017

issue

10

1 reference

3 December 2017

page(s)

1377-1383

1 reference

Chemotherapy for pancreatic carcinoma

3 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900271-5

7 January 2021

Lack of efficacy of high-dose leucovorin and fluorouracil in patients with advanced pancreatic adenocarcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900271-5

7 January 2021

Fluorouracil and high-dose leucovorin in previously untreated patients with advanced adenocarcinoma of the pancreas: results of a phase II trial

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900271-5

7 January 2021

Randomized trial of 5-fluorouracil and mitomycin C with or without streptozotocin for advanced pancreatic cancer. A Southwest oncology group study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900271-5

7 January 2021

Chemotherapy for advanced pancreatic cancer. A comparison of 5-fluorouracil, adriamycin, and mitomycin (FAM) with 5-fluorouracil, streptozotocin, and mitomycin (FSM).

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900271-5

7 January 2021

A phase III comparison trial of streptozotocin, mitomycin, and 5-fluorouracil with cisplatin, cytosine arabinoside, and caffeine in patients with advanced pancreatic carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900271-5

7 January 2021

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900271-5

7 January 2021

Phase I study of ZD9331 on short daily intravenous bolus infusion for 5 days every 3 weeks with fixed dosing recommendations

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900271-5

7 January 2021

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900271-5

7 January 2021

The determinatio of the number of patients required in a preliminary and a follow-up trial of a new chemotherapeutic agent

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900271-5

7 January 2021

10.1016/S0959-8049(03)00271-5

Identifiers

DOI

1 reference

3 December 2017

1 reference